Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, 19 years ≤ age ≥ 80 years~2. Those who be expected to do operation about non palpable breast lesion excision~3. Those who have lesion vial mammography and breast ultrasound~4. Written consent voluntarily to participate in this clinical trial~Exclusion Criteria:~1. Patients who be expected to do mastectomy~2. Patients with multiple tumor or diffuse microcalcification~3. Patients who have ink on invasive cancer or ductal carcinoma in situ despite 3 times local resection~4. Patients who were treated with moderate to severe radiotherapy~5. Patients who were treated with neoadjuvant Chemotherapy~6. Patients with active invading skin connective tissue disease~7. Patients with local progressing breast cancer or inflammatory local progressing breast cancer~8. Patients who have an allergy to investigational product or any of the component with the Investigational product~9. Patients who disagree about contraception for this clinical trial~10. A pregnant women or lactating women~11. Patients who participated in other clinical trials within the past 12 weeks from the date of informed consent~12. Patients who investigators determines unsuitable for this clinical trial

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- LuminoMark inj. 0.1mL (Type: EXPERIMENTAL): Injection LuminoMark inj. 0.1mL once in this study.
- LuminoMark inj. 0.2mL (Type: EXPERIMENTAL): Injection LuminoMark inj. 0.2mL once in this study.
- Charcotrace Inj. (Type: ACTIVE_COMPARATOR): Charcotrace Inj. about 0.3\~1mL

Based on this trial design, predict the completion outcome and termination type (if applicable).